TAS2R38

Across TCGA pan-cancer cohorts, TAS2R38 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated TAS2R38 data layer compared with 4 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TAS2R38 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R38 expression acts as an unfavorable survival marker, although some lineages such as SCLC and UCS show a favorable association.

LIHC, CHOL, and UCEC are the cancer types where TAS2R38 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.250	0.651	<.001	57	view →
CHOL	DFS	Tertile	II,III,IV	0.105	0.505	.012	51	view →
UCEC	DFS	Tertile	All	0.741	0.862	<.001	36	view →
SCLC	OS	Quartile	II,III,IV	0.779	0.305	.001	34	view →
BRCA	OS	Tertile	All	0.930	0.969	.014	24	view →
COAD	DFS	Quartile	All	0.683	0.847	.011	20	view →
MESO	OS	Tertile	IV	0.077	0.592	.019	18	view →
LAML	DFS	Tertile	All	0.409	0.670	.007	18	view →
LUAD	DFS	Tertile	IV	0.220	0.694	.006	18	view →
ACC	OS	Tertile	III,IV	0.271	0.623	.018	18	view →
UCS	OS	Median	IV	0.732	0.224	.018	12	view →
SKCM	DFS	Tertile	All	0.625	0.787	.005	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

TAS2R38–LIHC (OS)

Open the LIHC breakdown →